Stock comparison
JOHNSON & JOHNSON is 38.3x more valuable than GENMAB A/S by market capitalization ($622.64 B vs $16.27 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 38.3x more valuable than GENMAB A/S by market capitalization ($622.64 B vs $16.27 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 38.3x more valuable than GENMAB A/S by market capitalization ($622.64 B vs $16.27 B).
| Metric | GMAB | JNJ |
|---|---|---|
| Market cap | $16.27 B | $622.64 B |
| US-listed rank | #694 | #18 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | - | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 23.2x |
| SEC filings | 540 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 38.3x more valuable than GENMAB A/S by market capitalization ($622.64 B vs $16.27 B).
Full pages: GENMAB A/S and JOHNSON & JOHNSON, or browse the full rankings.